




**January 2011**

Volume 16 · Numbers 1/2

pp. 1–90



#### Cover Story

The leading story of this issue of *Drug Discovery Today*, by Peter Wipfler, Andrea Harrer, Georg Pilz, Katrin Oppermann, Eugen Trinkä and Jörg Kraus discusses those agents and treatment strategies that have emerged since the introduction of the first specific treatment for the disease, that is the immunomodulatory drug, interferon  $\beta$ , in the mid 1990s. In the last ten years or so, the number and variety of possible approaches has increased significantly and of particular interest is the development of oral treatments. The authors highlight the current state of approved and future therapies in this field.

# DRUG DISCOVERY TODAY

## REVIEWS

### KEYNOTE

- 8 Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options**

*Peter Wipfler, Andrea Harrer, Georg Pilz, Katrin Oppermann, Eugen Trinkä and Jörg Kraus*

- 22 Angiotensin II receptors and drug discovery in cardiovascular disease**

*Chiranjib Dasgupta and Lubo Zhang*

### GENE TO SCREEN

- 35 New avenues to target Wnt/ $\beta$ -catenin signaling**

*Folkert Verkaar and Guido J.R. Zaman*

### INFORMATICS

- 42 Understanding infectious agents from an *in silico* perspective**

*Joo Chuan Tong and Lisa F.P. Ng*

### POST SCREEN

- 50 Creativity, innovation and lean sigma: a controversial combination?**

*Craig Johnstone, Garry Pairaudeau and Jonas A. Pettersson*

- 58 Characterization of protein therapeutics by mass spectrometry: recent developments and future directions**

*Guodong Chen, Bethanne M. Warrack, Angela K. Goodenough, Hui Wei, David B. Wang-Iverson and Adrienne A. Tymiak*

- 65 The graphical representation of ADME-related molecule properties for medicinal chemists**

*Timothy J. Ritchie, Peter Ertl and Richard Lewis*

- 73 Characteristics of orphan drug applications that fail to achieve marketing approval in the USA**

*Harald E. Heemstra, Hubert G.M. Leufkens, R.P. Channing Rodgers, Kui Xu, Bettie C.G. Voordouw and M. Miles Braun*

- 81 Early chemical development at Legacy Wyeth Research**

*Michael K. O'Brien, Michael Kolb, Terrence J. Connolly, J. Christopher McWilliams and Karen Sutherland*